IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
L Lee DupuisJohn Doyle

Abstract

We currently calculate area under the busulfan concentration time curve (AUC) using 7 plasma busulfan concentrations (AUC7) drawn after the first of 16 i.v. busulfan doses given as a 2-hour infusion every 6 hours. The aim of this study was to develop and validate limited sampling strategies (LSSs) using 3 or fewer busulfan concentration values with which to reliably calculate AUC in children undergoing hematopoietic stem cell transplant (HSCT). Children in the development group (44) received i.v. busulfan at Sick Kids; the validation group consisted of 35 children who received care at CHU Ste-Justine. Busulfan doses given and subsequent plasma busulfan concentrations were recorded. LSSs using 1 to 3 concentration-time points were developed using multiple linear regression. LSS were considered to be acceptable when adjusted r(2) > 0.9, mean bias <15% and precision <15%. Extent of agreement between the AUC7 values and the LSS AUC was assessed by the intraclass correlation coefficient (ICC) and Bland-Altman (BA) analysis. Agreement was considered to be excellent when the lower limit of the 95% confidence limit of the ICC exceeded 0.9 and when the limits of agreement in the BA analysis were +/-15% for both AUC and dose. Administrat...Continue Reading

References

Oct 14, 1983·Journal of Chromatography·M Hassan, H Ehrsson
Dec 5, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·William P VaughanDonna E Salzman

❮ Previous
Next ❯

Citations

May 29, 2012·European Journal of Drug Metabolism and Pharmacokinetics·Ji-Han HuangQing-Shan Zheng
Jul 21, 2009·Expert Opinion on Drug Metabolism & Toxicology·Jeannine S McCune, Leona A Holmberg
May 4, 2013·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ji-Han HuangQing-Shan Zheng
Oct 4, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·L Lee DupuisTal Schechter
May 31, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jessica WardWilliam T Tse
May 29, 2012·Cancer Science·Yachiyo KuwatsukaUNKNOWN Nagoya Blood and Marrow Transplantation Group
May 16, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jamie H ZaoL Lee Dupuis
Dec 8, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Robert ChiesaSarah Marktel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.